Avacta Group plc (GB:AVCT) has released an update.
Avacta Group plc, a UK-based life sciences company, has announced the expansion of its oncology pipeline with two new preclinical assets, AVA6103 and AVA7100. These assets, developed using the company’s proprietary pre|CISION® platform, aim to enhance targeted cancer treatments by delivering drugs directly to tumors while minimizing exposure to healthy tissues. This strategic move highlights Avacta’s commitment to addressing unmet needs in cancer therapy.
For further insights into GB:AVCT stock, check out TipRanks’ Stock Analysis page.
